NYSEAMERICAN:OGEN - Oragenics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.9499 +0.04 (+4.40 %) (As of 02/17/2019 11:32 AM ET)Previous Close$0.9499Today's Range$0.90 - $0.986052-Week Range$0.38 - $4.20Volume2.59 million shsAverage Volume1.39 million shsMarket Capitalization$27.96 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida. Receive OGEN News and Ratings via Email Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:OGEN Previous Symbol CUSIPN/A Webwww.oragenics.com Phone+1-813-2867900Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees6 Outstanding Shares29,433,000Market Cap$27.96 million OptionableNot Optionable Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions What is Oragenics' stock symbol? Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN." When did Oragenics' stock split? How did Oragenics' stock split work? Oragenics's stock reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split. How were Oragenics' earnings last quarter? Oragenics Inc (NYSEAMERICAN:OGEN) released its quarterly earnings data on Tuesday, November, 13th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.13. View Oragenics' Earnings History. Has Oragenics been receiving favorable news coverage? Media coverage about OGEN stock has trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oragenics earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. Are investors shorting Oragenics? Oragenics saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,699,060 shares, an increase of 35.8% from the January 15th total of 1,250,733 shares. Based on an average trading volume of 1,385,288 shares, the days-to-cover ratio is currently 1.2 days. Currently, 6.7% of the company's shares are sold short. View Oragenics' Current Options Chain. Who are some of Oragenics' key competitors? Some companies that are related to Oragenics include Covalon Technologies (COV), Immutep (IMM), Medicure (MPH), Acasti Pharma (ACST), CEL-SCI (CVM), IntelGenx Technologies (IGX), Orgenesis (ORGS), Botanix Pharmaceuticals (BOT), Promis Neurosciences (PMN), Protalix Biotherapeutics (PLX), Pediapharm (PDP), Bionomics (BNO), Ampio Pharmaceuticals (AMPE), Helix Biopharma (HBP) and Actinium Pharmaceuticals (ATNM). Who are Oragenics' key executives? Oragenics' management team includes the folowing people: Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. ConsultantDr. Guojun Nie Ph.D., Director of Process Devel. Who are Oragenics' major shareholders? Oragenics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.40%), Virtu Financial LLC (0.47%) and Barclays PLC (0.46%). View Institutional Ownership Trends for Oragenics. Which major investors are buying Oragenics stock? OGEN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Virtu Financial LLC and Barclays PLC. View Insider Buying and Selling for Oragenics. How do I buy shares of Oragenics? Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Oragenics' stock price today? One share of OGEN stock can currently be purchased for approximately $0.9499. How big of a company is Oragenics? Oragenics has a market capitalization of $27.96 million. Oragenics employs 6 workers across the globe. What is Oragenics' official website? The official website for Oragenics is http://www.oragenics.com. How can I contact Oragenics? Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900. MarketBeat Community Rating for Oragenics (NYSEAMERICAN OGEN)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 60 (Vote Outperform)Underperform Votes: 61 (Vote Underperform)Total Votes: 121MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: Why is the ex-dividend date different from the record date?